Tuberc Respir Dis.
2013 Jan;74(1):1-6.
Recent Advances in Idiopathic Pulmonary Fibrosis
- Affiliations
-
- 1Department of Internal Medicine, KEPCO Medical Center, Seoul, Korea.
- 2Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. nanjung@korea.ac.kr
Abstract
- The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Two cases of idiopathic pulmonary fibrosis
- Recent Advances in Molecular Basis of Lung Aging and Its Associated Diseases
- Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia
- An ROC study detecting ability of idiopathic pulmonary fibrosis using digital radiography
- Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
